Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
businesswire.com
⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in